Company Performance Metrics
Bernard H. Cohen: Vice President and CFO- Joseph Cummins: President
Amarillo Biosciences is a specialty biopharmaceutical company developing a patented formulation of interferon-alpha that's given orally in low doses, making it safer and less expensive than current injectable formulations. The company engaged in the discovery and development of novel biopharmaceuticals, technologically innovative medical
treatments, and specialty consumer products.
Amarillo Biosciences also focuses on the advancement of low-dose oral interferon as a therapeutic treatment for numerous indications such as thrombocytopenia, Sjögren's syndrome, hepatitis C virus (HCV) and influenza, a potential multi-million dollar market opportunity. Low-dose oral interferon has been shown to have fewer side effects and is less costly than high-dose injectable interferon.
The company's goal is to introduce cutting edge products that actively stimulate and rejuvenate the human body to combat disease and enhance the ability to heal.
